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ABSTRACT Hepatitis C virus (HCV) species tropism is incompletely understood. We have previously shown that at the level of
entry, human CD81 and occludin (OCLN) comprise the minimal set of human factors needed for viral uptake into murine cells.
As an alternative approach to genetic humanization, species barriers can be overcome by adapting HCV to use the murine ortho-
logues of these entry factors. We previously generated a murine tropic HCV (mtHCV or Jc1/mCD81) strain harboring three mu-
tations within the viral envelope proteins that allowed productive entry into mouse cell lines. In this study, we aimed to charac-
terize the ability of mtHCV to enter and infect mouse hepatocytes in vivo and in vitro. Using a highly sensitive, Cre-activatable
reporter, we demonstrate that mtHCV can enter mouse hepatocytes in vivo in the absence of any human cofactors. Viral entry
still relied on expression of mouse CD81 and SCARB1 and was more efficient whenmouse CD81 and OCLNwere overexpressed.
HCV entry could be significantly reduced in the presence of anti-HCV E2 specific antibodies, suggesting that uptake of mtHCV is
dependent on viral glycoproteins. Despite mtHCV’s ability to enter murine hepatocytes in vivo, we did not observe persistent
infection, even in animals with severely blunted type I and III interferon signaling and impaired adaptive immune responses.
Altogether, these results establish proof of concept that the barriers limiting HCV species tropism can be overcome by viral ad-
aptation. However, additional viral adaptations will likely be needed to increase the robustness of a murine model system for
hepatitis C.
IMPORTANCE At least 150 million individuals are chronically infected with HCV and are at risk of developing serious liver dis-
ease. Despite the advent of effective antiviral therapy, the frequency of chronic carriers has only marginally decreased. Amajor
roadblock in developing a vaccine that would prevent transmission is the scarcity of animal models that are susceptible to HCV
infection. It is poorly understood why HCV infects only humans and chimpanzees. To develop an animal model for hepatitis C,
previous efforts focused onmodifying the host environment of mice, for example, to render themmore susceptible to HCV in-
fection. Here, we attempted a complementary approach in which a laboratory-derived HCV variant was tested for its ability to
infect mice. We demonstrate that this engineered HCV strain can enter mouse liver cells but does not replicate efficiently. Thus,
additional adaptations are likely needed to construct a robust animal model for HCV.
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At least 150 million individuals worldwide are chronically in-fected with hepatitis C virus (HCV). Chronic HCV infection
is associated with severe liver disease, including fibrosis, cirrhosis,
and hepatocellular carcinoma. Treatment options have drastically
improved in recent years, and it is now possible to effectively cure
HCV infection in themajority of patients.However, effectiveways
to prevent infection, for example via vaccination, remain elusive.
To systematically test and prioritize vaccine candidates, develop-
ment of an immunocompetent animal model, optimally with in-
heritable susceptibility to HCV, remains a high priority.
HCV exhibits a narrow and mechanistically incompletely un-
derstood species tropism. While humans and chimpanzees are
readily susceptible to HCV infection, most other species—with
the exception of intermittent, sporadic viremia in tree shrews—
appear to be resistant (reviewed in reference 1). Resistance ofmice
to HCV is multifactorial and determined at least by blocks in viral
entry and replication (reviewed in reference 2). HCV utilizes a
large number of host factors to enter its host cells, the human
hepatocyte (reviewed in reference 3). These factors include glycos-
aminoglycans (GAGs) present on heparan sulfate proteoglycans
(HSPGs), low-density-lipoprotein receptor (LDLR) (4, 5), CD81
(6), scavenger receptor class B member 1 (SCARB1) (7), the tight
junction claudin proteins, including claudin-1 (CLDN1) (8) and
CLDN6 and CLDN9 (9), occludin (OCLN) (10, 11), the receptor
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tyrosine kinases epidermal growth factor receptor (EGFR), and
ephrin receptor A2 (EphA2) (12), the cholesterol transporter
Niemann-Pick C1-like 1 (NPC1L1) (13), transferrin receptor 1
(TfR1) (14), and the cell death-inducing DFFA-like effector b
(CIDEB) (15). It was previously shown that CD81 (6), SCARB1 (7)
and the two tight junction proteins CLDN1 (8) and OCLN (10,
11) are all required for uptake into human and also rodent cells
but that only CD81 and OCLN need to be of human origin to
facilitate this process (11). Indeed, transient adenoviral (16) or
stable transgenic (17) expression of human CD81 and OCLN in
mouse hepatocytes facilitates HCV uptake. The differential abili-
ties of mouse and human CD81 and OCLN to support viral entry
have been mapped to amino acids in their second extracellular
loops (11, 18). While infectious HCV particles can assemble in
mouse liver cells in vitro (19) and in vivo (17), HCV RNA replica-
tion in mice is limited, presumably by a combination of innate
antiviral immune responses (17, 20–23) and possibly by poor
compatibility between murine orthologues of replication cofac-
tors and the virally encoded components of the HCV replication
machinery (1).
Complementary to the host genetic adaptation approach, ad-
aptation of HCV to rodent hosts is an alternative strategy for es-
tablishing a mouse model for hepatitis C. We previously used an
unbiased selection approach to adapt an HCV genotype 2a strain,
Jc1, to use mouse CD81 (24). We identified three adaptive muta-
tions in the HCV envelope proteins E1 and E2 that facilitated
uptake into cell lines expressing human SCARB1, CLDN1,OCLN,
and mouse, rat, or hamster CD81 (24). The mutations signifi-
cantly increased the affinity of the virus for the large extracellular
loops of human CD81, suggesting an indirect enhancement by
exposing a CD81 binding site. The mutations in the mouse CD81
(mCD81)-adapted, i.e., murine tropic, virus (mtHCV or Jc1/
mCD81) altered usage of human SCARB1 (hSCARB1) and hu-
manOCLN (hOCLN). Blocking antibodies against hSCARB1 and
silencing of hOCLN had a less pronounced effect on the entry of
the mutant virus compared to the parental strain, suggesting that
the mCD81-adapted virus was less dependent on hSCARB1 and
hOCLN. Finally, mouse fibroblasts expressing murine CD81,
SCARB1, CLDN1, and OCLN supported the uptake of adapted
virus. This entry could be blocked with anti-mCD81 antibodies,
indicating that the species-specific restriction to human OCLN
was altered while dependence on CD81 was maintained.
Here, we aimed to extend this work and directly test whether
our mtHCV harboring mutations that facilitate efficient engage-
ment of murine CD81 and OCLN could infect murine primary
hepatocytes in vitro and in vivo. We demonstrate that mtHCV can
enter mouse hepatocytes in cell culture and that this uptake is
dependent on the adaptive mutations present in HCV E1 and E2.
Using a sensitive reporter, we show that mtHCV enters mouse
hepatocytes in vivo in an HCV glycoprotein-dependent manner.
Although hepatic overexpression of mouse CD81 and OCLN en-
hancesHCVentry, uptake is not dependent on ectopic expression,
andmtHCV is capable of utilizing the endogenous proteins, albeit
at low efficiency. Previous data suggest that innate immunity re-
stricts HCV replication in mouse hepatocytes in vitro (20–22, 25)
and in vivo (17). Mice with targeted disruptions of signal trans-
ducer and activator of transcription factor 1 (STAT1), which have
severely impaired type I and III interferon (IFN) responses, did
not develop persistent viremia following infection. Engraftment
of STAT1-deficient mouse hepatocytes into immunodeficient
mice with liver injuries allowed us to directly test whether murine
adaptive immune responses further antagonize HCV replication.
However, in the absence of functional B, T, and natural killer cells,
mtHCV infection in murine hepatocytes was not further en-
hanced. Collectively, these data suggest that additional barriers
limit propagation ofmtHCV inmice. The low uptake efficiency of
mtHCV into mouse hepatocytes expressing endogenous levels of
viral entry factors may preclude efficient spread, which may be
necessary to establish persistence. In addition, the efficiency of
postentry steps of the viral life cycle could conceivably be im-
proved with human host factors important for HCV replication,
assembly, and/or egress. Thus, additional, currently unknown
proviral factors and/or negative regulators antagonizingHCVwill
have to be identified to enhance HCV replication and assembly in
mouse cells.
RESULTS
mtHCV-specific adaptations are maintained upon long-term
replication in vivo. It was previously demonstrated that cell cul-
ture adaptivemutations that increased the level of viral replication
in vitro could potentially compromise viral fitness in vivo (26).
Thus, we aimed to test whether the three adaptive mutations in
Jc1/mCD81 affected its viral fitness in vivo and whether they were
stably maintained during long-term in vivo replication.
We took advantage of a previously established human liver-
uPA-SCID mouse model that stably supports HCV replication
(27, 28). Stable engraftment with human hepatocytes was deter-
mined by monitoring serum levels of human albumin (data not
shown). We infected the mice with 6  105 TCID50 (50% tissue
culture infective doses) of Jc1 or Jc1/mCD81 and observed stable
and comparable HCV RNA levels for both Jc1- and Jc1/mCD81-
infected mice for about 56 days (Fig. 1a). Eight weeks after inoc-
ulation of Jc1/mCD81, we deep sequenced the genes of the enve-
lope glycoproteins E1 and E2, the signal peptides of E1 and p7. All
three adaptive mutations—L216F, V388G, and M405T—were
conserved 100% between the viral inoculum (Fig. 1b) and the
mouse-passaged virus (Fig. 1c). Taken together with the observa-
tion that infection with both Jc1 and Jc1/mCD81 leads to compa-
rable HCV RNA serum levels, these data demonstrate that the
three adaptive mutations do not diminish the replication capacity
of Jc1/mCD81 in vivo. Furthermore, neither virus acquired any
additional adaptive mutation(s) upon long-term in vivo replica-
tion.
Jc1/mCD81 is capable of entering murine hepatocytes in
vitro and in vivo. We previously demonstrated that ectopic expres-
sion of themurine orthologues of the four canonical HCV entry fac-
tors—SCARB1, CD81, CLDN1, and OCLN—supports cell entry of
HCV pseudoparticles (HCVpp) packaged with envelopes of
mtHCV (mtHCVpp) (24). However, initial attempts to quantify
mtHCVpp uptake into primarymurine hepatocytes in cell culture
failed (24). Since HCV RNA replication is inefficient in murine
hepatocytes, we adopted a Jc1 genome expressing a Gaussia lu-
ciferase reporter [Jc1(p7nsGluc2A)] (29) that allows highly sensi-
tive detection of HCV entry by luciferase secretion following ini-
tial translation of the HCV genome. We engineered the three
adaptive mutations of mtHCV into Jc1(p7nsGluc2A), yielding
Jc1/mCD81(p7nsGluc2A). Infection of mouse primary hepato-
cytes isolated from C57BL/6 mice with Jc1/mCD81(p7nsGluc2A)
resulted in a 2- to 4-fold-higher luciferase signal than infection
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with the parental virus (Fig. 2a), suggesting that the three adaptive
mutations enabled viral uptake, albeit at low efficiency.
To directly test whether mtHCV is capable of entering mouse
hepatocytes in vivo, we utilized a highly sensitive reporter inwhich
cellularly encoded firefly luciferase is activated by Cre recombi-
nase expressed in a bicistronic HCV genome configuration (BiCre-
Jc1) (16). Analogous to previous studies, we expressed human or
mouse CD81, SCARB1, CLDN1, and OCLN via an adenoviral
vector in the livers of Rosa26-Fluc mice (30) and infected animals
with BiCre-Jc1 or BiCre-Jc1/mCD81. In accordance with previ-
ously published data, BiCre-Jc1 entered mouse hepatocytes over-
expressing the human orthologues of the canonical entry factors
but not mouse hepatocytes overexpressingmurine orthologues of
the canonical entry factors. In contrast, the bicistronic HCV ge-
nome harboring the adaptivemutations in E1 and E2 activated the
reporter equally well in mice overexpressing entry factors from
either humans or mice (Fig. 2b and c). Collectively, these data
demonstrate that the three adaptive mutations in E1 and E2 en-
able uptake of HCV into mouse primary hepatocytes in vitro and
in vivo.
Efficiency of mtHCV uptake in vivo positively correlates
with the viral dose and expression levels of HCV entry factors.
To assess the efficiency of mtHCV uptake in vivo, we performed
dose-response experiments titrating either the level of overexpres-
sion ofmouse CD81, SCARB1, CLDN1, andOCLNwhile keeping
the viral inoculum constant (Fig. 3a and b) or overexpressing
mouse canonical entry factors and varying the inoculum dose
(Fig. 3c and d). Rosa26-Fluc mice were injected intravenously
with low (1 108 adenoviral [AdV] particles/mouse), intermedi-
ate (1 109 or 1 1010 AdV particles/mouse), or high (1 1011
FIG 1 Evolution ofmtHCVduring long-term replication in uPA-SCIDmice repopulated with human hepatocytes. (a)Mice were inoculated with an equal dose
ofwild-typeHCVandmtHCV.Virus plasma levelswere determined at the indicated timepoints postinoculation. (b and c) Evolution ofmtHCV sequence during
chronic infection inmice. TheE1-E2-p7 coding region of the virus inoculum (b) andof the virus population circulating 8weeks postinoculation (c)was amplified
and sequenced using the Roche 454 platform. The x axis represents nucleotide position relative to the reference sequence. The y axis represents nucleotide
coverage across the E1-E2-p7 coding region with synonymous (dS) and nonsynonymous (dN) single nucleotide polymorphism (SNP) frequencies in the viral
population relative to the reference sequence highlighted. The mtHCV-specific adaptations L216F, V388G, and M405T are marked with red asterisks.
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AdV particles/mouse) doses of adenoviral particles or no adeno-
virus and subsequently infectedwith cell culture-produced BiCre-
Jc1/mCD81 (2  107 TCID50/mouse). The highest expression of
HCV entry factors enhanced the signal of the luminescent re-
porter 6- to 7-fold compared with mice that received the lowest
dose of HCV entry factors (Fig. 3a and b). These data are in accor-
dance with our previous data demonstrating that uptake of HCV
with native E1/E2 glycoproteins is more efficient in mouse hepa-
tocytes expressing high levels of human CD81, SCARB1, CLDN1,
and OCLN (16).
Of note, even in the absence of ectopic expression of HCV
entry factors, mtHCV was still capable of entering mouse hepato-
cytes, albeit at very low levels (Fig. 3a, left panel). This suggests
that endogenous expression levels of HCV entry factors in the
mouse liver may suffice for viral uptake.
We observed a similar correlation when mice overexpressing
mouse CD81, SCARB1, CLDN1, and OCLN or just CD81 and
OCLN were infected with various doses of cell culture-produced
BiCre-Jc1/mCD81. The higher the inoculum, the more robustly
the luminescent reporter was activated in mice overexpressing
murine versions of all fourHCV entry factors (ca. 4- to 5-fold over
background) (Fig. 3c and d). Because viral uptake relied on en-
dogenous expression of SCARB1 and CLDN1, in mice overex-
pressing onlymouseCD81 andOCLN, the signal was about 3-fold
over background. In mice not injected with HCV entry factor-
expressing adenoviruses, luminescent reporter activity was even
lower, only 2-fold over background levels (Fig. 3d).
Collectively, these data demonstrate that mtHCV entry into
murine hepatocytes is more efficient when mouse CD81,
SCARB1, CLDN1, and OCLN are not limiting. It should be noted
that these constraints are due in part to the detection limit of the
Cre-based reporter assay.
Quantification of the frequency ofHCV-infected cells.To es-
timate the number of HCV-infected liver cells, we used an indica-
tor mouse strain in which Cre leads to activation of a nucleus-
localized green fluorescent protein (GFP)/-galactosidase (GNZ)
reporter (Rosa26-GNZ) (31). In approximately 0.07 to 0.09% of
mouse hepatocytes, GFP fluorescence was detected when uptake
was solely mediated by the endogenous murine entry factors after
a challenge with a dose of 2 107 TCID50 (Fig. 4). Upon adeno-
viral overexpression of mouse CD81, SCARB1, CLDN1, and
OCLN, the frequency increased roughly 10-fold, reaching levels
that were about one-half of those reported in mice expressing
human orthologues of the canonical entry factors (1 to 1.5%) (16,
17). Following previously established protocols (32), we also in-
cludedDNA intercalating dyes (Hoechst) to determine any differ-
ences in the ability of mono-, bi-, andmultinucleated hepatocytes
to support HCV uptake. Infection frequencies were largely equiv-
alent among these subsets of hepatocyte populations, with slightly
reduced numbers in multi- versus mono- or binucleated cells.
mtHCV enters hepatocytes in vivo in a glycoprotein-de-
pendent manner. To demonstrate that mtHCV entry into mouse
hepatocytes is dependent on the interaction of the viral envelope
with cellularly encoded receptors, we performed blocking and
loss-of-function experiments (Fig. 5). First, we took advantage of
the well-characterized broadly neutralizing antibody AR4A,
which binds to an epitope in the HCV envelope protein E2 (33).
mtHCV was preincubated with various concentrations of either
AR4A or an isotype control antibody (B12) and injected into
Rosa26-Fluc mice expressing mouse CD81, SCARB1, CLDN1,
andOCLN. Blockadewith AR4A led to a 30 to 40%decrease in the
luciferase signal at the highest antibody concentrations (Fig. 5a).
For comparison, preincubation of the parental BiCre-Jc1 strain
resulted in comparable, although slightly more effective (60 to
70%), blockade in Rosa26-Fluc mice expressing human CD81,
SCARB1, CLDN1, and OCLN (Fig. 5a). These data suggest that
FIG 2 mtHCV can enter mouse hepatocytes in vitro and in vivo. R26-LSL-
Fluc mice were injected with 1011 adenoviral particles encoding human (h) or
mouse (m) CD81, SCARB1, CLDN, and OCLN. Bioluminescence was mea-
sured at 72 h postinjection of 2  107 50% tissue culture infectious doses
(TCID50) of cell culture-producedmurine tropic (mt) or wild-type (wt)HCV-
Cre. (a) Primary hepatocytes isolated from C57BL/6 mice were plated on
collagen-coated plates, and monolayers were infected with Jc1(p7nsGluc2A)
or Jc1/mCD81Gluc2A with the indicated numbers of infectious particles (as
titered on Huh-7.5 cells) per primary hepatocyte. Luciferase activity was mea-
sured 48 h postinfection. Data are represented as the signal ofmtHCV over the
parental strain. (b) Representative pseudo-colored images. (c) Quantitation of
total photon flux/second (n  4). Values are means plus standard deviations
(SD) (error bars).
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uptake of HCV and mtHCV engaging human or mouse HCV
entry factors, respectively, is dependent on HCV glycoproteins.
To further explore this process, we employed mice with tar-
geted disruptions in the genes encoding CD81 (CD81/) or
SCARB1 (SCARB1/) that we crossed to the Rosa26-Fluc back-
ground (Fig. 5b). We focused our analysis on these twomolecules
since there is strong evidence that both CD81 and SCARB1 inter-
act directly with lipoviral HCV particles, unlike many of the other
HCV entry factors. CD81/ and SCARB1/mice and, as con-
trols, mice with both alleles were injected with adenoviruses de-
livering the indicated combinations of the canonical entry factor
mouse orthologues. In CD81/ mice overexpressing mouse
SCARB1, CLDN1, and OCLN (Fig. 5b, 5th column from the left),
the uptake efficiency was reduced by 90% compared with mice
with the endogenous CD81 and treated with the same combina-
tion of adenoviruses (Fig. 5b, 2nd column from the left). Likewise,
in SCARB1/ mice overexpressing mouse CD81, CLDN1, and
OCLN (Fig. 5b, 6th column from the left), the uptake efficiency
was reduced by ca. 85% compared to SCARB1/ mice treated
with the same combination of adenoviruses (Fig. 5b, 3rd column
from the left). While previous in vitro experiments using anti-
SCARB1blocking suggested thatmtHCVentrymay be less depen-
dent on SCARB1, our in vivo experiment establishes that mtHCV
requires both CD81 and SCARB1 to enter murine hepatocytes in
vivo.
mtHCV does not replicate in STAT1-deficient mice. To test
whether mtHCV may not only enter but also go through later
stages of the viral life cycle, we analyzed postentry steps in vivo.
Previous studies demonstrated that antiviral defenses, in particu-
lar type I and III IFN-dependent pathways, interfere with HCV
RNA replication in mouse cell lines and in mice (17, 20–23, 33,
FIG 3 Efficiency of mtHCV uptake positively correlates with HCV entry factor expression levels and challenge dose. (a and b) Rosa26-Fluc mice were injected
with limiting dilutions of adenoviruses encoding mouse CD81 (mCD81), SCARB1, CLDN1, and OCLN prior to infection with 1 106 TCID50 mtHCV-Cre. (c
and d) Rosa26-LSL-Flucmice were injected with 1011 particles of adenoviruses encodingmouse CD81, SCARB1, CLDN1, andOCLNormock injected, followed
24 h later by infectionwith the indicated doses ofmtHCV-Cre or, as a control, PBS (n 3). (a and c)Representative pseudocolored images; (b andd) quantitation
of bioluminescent signal (n 3). Data were acquired 72 h following HCV infection. Values are means SD (error bars).
FIG 4 Quantitation of the frequency of mtHCV-infected hepatocytes in vivo.
Rosa26-LSL-GNZmicewere injectedwith 1 1011 adenoviral particles encoding
mouse entry factors (mEF) or not injected with AdV and subsequently infected
with 1 106 TCID50mtHCV-Cre. Seventy-two hours following infection, single-
cell suspensions were prepared by liver perfusion with collagenase. Cells were
counterstained with DRAQ5 to distinguish betweenmono-, bi-, andmultinucle-
ated (or multiploid) cells. The total frequency of infected hepatocytes within the
subpopulationswasdeterminedbyflowcytometry(n3).ValuesaremeansplusSD.
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34). Thus, we tested the replicative fitness of mtHCV inmice with
a targeted disruption of STAT1 (Fig. 6). STAT1 knockoutmice are
severely impaired in type I and III IFN signaling. We previously
showed that STAT-deficient mice transgenically expressing hu-
man CD81, SCARB1, CLDN1, and OCLN support low levels of
HCV infection over several weeks (17). While we were also able
to detect HCV RNA—presumably from the residual inocu-
lum—4h following infection of STAT1/micewith cell culture-
produced mtHCV (5 106 TCID50/mouse, intravenously), none
of the animals were consistently viremic at any of the later time
points. Furthermore, we did not detect any differences between
STAT1/ and isogenic wild-type control animals.
Minimal evidence for mtHCV RNA replication in the ab-
sence of antiviral innate and adaptive immune responses. It is
conceivable that those cells inwhichmtHCVmay start to replicate
are rapidly cleared by the murine adaptive immune system. Thus,
to test whether mtHCV may establish persistent infection in
highly immunocompromised animals in which both innate and
adaptive responses were compromised, we transplanted Alb-uPA
SCID/beige mice (28) with hepatocytes isolated from STAT1/
mice. Consistent with previously published data (35), transplan-
tation of 2 105 or 4 105 mouse hepatocytes from STAT1/
mice rescued Alb-uPA SCID/beige mice from acute liver failure
and resulted in successive weight gain (data not shown). Stably
engrafted animals were injected with cell culture-produced
mtHCV (1.33  106 TCID50), and viremia was monitored for
8 weeks. In contrast to human liver chimeric mice in which
mtHCV caused high-level, persistent viremia (Fig. 1), most mu-
rine liver chimeric mice remained below the limit of detection
(Table 1). A singlemouse (B620R) became viremic at a single time
point 4 weeks following inoculation, but viremia was just slightly
above the limit of detection of 300 IU/ml. These data suggest that
mtHCV does not replicate in murine hepatocytes or replicates at
levels below the detection limit of our assays.
DISCUSSION
Themolecular basis forHCV’s narrow host range remains incom-
pletely understood. This has posed challenges for developing
small animal models for HCV infection. In rodent cells, the HCV
life cycle is blocked at the level of entry and at postentry steps.
HCV’s inability to enter rodent cells can be explained by differ-
ences in critical residues in the second extracellular loops of CD81
(36, 37) and OCLN (18). Consequently, expression of human
CD81 and OCLN, along with human or mouse SCARB1 and
CLDN1, facilitates HCV uptake in mouse cells in vitro (11) and in
vivo (16, 17, 38).
As an alternative to genetic host adaptations, we have previ-
ously demonstrated that the block of HCV at the level of entry can
also be overcome by viral adaptation (24). Using an in vitro selec-
tion approach, we identified mutations within HCV E1 and E2
that increased the affinity of the viral envelope for mouse CD81.
These mutations appeared to more broadly affect the conforma-
tion of the viral envelope, as the resulting mCD81-adapted strain
was also less dependent on human OCLN and could enter cell
lines expressing only mouse CD81, SCARB1, CLDN1, and OCLN
(24). Here, we show that Jc1/mCD81 can also infect murine pri-
mary hepatocytes in vitro and in vivo. Uptake of thismtHCV strain
is dependent on interactions of the viral glycoproteins with mu-
rine orthologues of HCV entry factors, specifically CD81 and
SCARB1. However, uptake of mtHCV into mouse hepatocytes
appears to be rather inefficient, as viral uptake can be detected in
only 0.05 to 0.1% of murine hepatocytes (Fig. 4). This is further
corroborated by our observation that adenoviral overexpression
of themurine orthologues increased uptake efficiency (Fig. 3). It is
conceivable that additional adaptive mutations may be necessary
to facilitate more efficient entry. At the same time, it cannot be
ruled out that molecules present on the surfaces of mouse hepa-
FIG 5 Uptake of mtHCV in vivo can be blocked with anti-HCV E2-specific
antibodies and is dependent on endogenous expression of mouse CD81 and
SCARB1. (a) R26-LSL-Fluc mice were injected with 1  1011 particles of ad-
enoviruses expressing mouse CD81, SCARB1, CLDN1, and OCLN. mtHCV-
Cre was incubated with the indicated doses of anti-HCV E2 (clone AR4A) or
an anti-HIV isotype control antibody (clone B12) for 1 h prior to injection
(1  106 TCID50) and 24 h after adenoviral delivery (n  3). Data were ac-
quired 72 h followingHCV infection. Values aremeans SD. (b) Rosa26-Fluc
mice were crossed withmCD81/ ormSCARB1/mice, and offspring with
the indicated zygosities for the respective mutant alleles were injected with the
indicated combinations of AdVs encoding mouse CD81 (mCD81), SCARB1,
CLDN1, and OCLN and 24 h later with 2  107 TCID50 BiCre-Jc1 (n  4).
Luminescence was quantified 72 h followingHCV infection. Values aremeans
plus SD.
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tocytes but presumably not human hepatocytes interfere with vi-
ral uptake.
We further explored whether Jc1/mCD81 could also proceed
through other steps of the viral life cycle. Numerous in vitro stud-
ies have demonstrated that type I and III IFN-dependent antiviral
defenses appear to act more efficiently to shut down HCV infec-
tion in rodent cells than in human cells (25, 39). For example,
fibroblast and immortalized hepatic cell lines frommice deficient
in interferon regulatory factor 3 (IRF3), IRF7, mitochondrial an-
tiviral signaling protein (MAVS), and STAT1 support HCV RNA
replication more efficiently than wild-type cells do (17, 20–23).
Thus, we employed STAT1-deficient mice, which are severely im-
paired in type I and III IFN signaling and animals lacking both
functional innate and adaptive immune responses. We previously
showed that STAT/ mice transgenically expressing human
CD81, SCARB1, CLDN1, and OCLN became viremic, albeit at
low levels (17). Other studies in HCV entry factor transgenicmice
on an ICR background suggested that HCV infection could be-
come chronic even in fully immunocompetent animals (38).
Blunting cell intrinsic immunity and even both innate and
adaptive immunity was not sufficient to establish persistent HCV
infection. This may be explained by a combination of the very low
entry efficiency and replication of mtHCV in mouse hepatocytes
in the absence of ectopic (over)expression of the human ortho-
logues of HCV entry factors. Future efforts will have to focus on
identifying putatively missing human-specific positive regulators
of HCV replication in mouse hepatocytes or alternatively, identi-
fying mutations that increase HCV replicative fitness in mouse
cells. The latter approach has been attempted, but mutations that
arose during replication of antibiotic-resistant HCV replicons in
mouse cells seemed to be random rather than adaptive (40), as
none substantially enhanced replication efficiency in the murine
cell environmentwhen reintroduced into the parental subgenome
(41).
Conceivably, it may be simpler to adapt HCV to other species
that are genetically more closely related to humans than mice.
Results from prior studies suggested that several other nonhuman
primate species are resistant to HCV infection (42, 43). However,
more-recent work has shown that hepatocyte-like cells derived
from pig-tailedmacaques induced pluripotent stem cells (44) and
primary adult hepatocytes from rhesus macaques (45) can sup-
port the entire HCV life cycle. When rhesus macaque hepatocytes
FIG 6 Infection of mice with blunted innate immunity does not result in persistent infection. Mice with a fully intact innate immune system (wild-type [WT])
or lacking STAT1 were infected with 5 106 TCID50 of Jc1 or Jc1/mCD81. HCVRNA levels (number of copies [cop] per milliliter) weremeasured by qRT-PCR
at the indicated time points. Each symbol represents the value f or an individual animal. The dashed line shows the limit of detection (l.o.d.).
TABLE 1 Infection of uPA-SCID mice engrafted with STAT1-deficient murine hepatocytes with mtHCV does not result in stable viremiaa
Group Mouse IDb Hepatocyte donor Hepatocyte dose
Viral RNA (IU/ml) at the following time postinfection (wk)c:
2 3 4 5 8
RO K1389L STAT-1 KO 2.10E5 375 300 300 300 150
K1389RL STAT-1 KO 2.10E5 375 300 300 300 150
IP B620 STAT-1 KO 4.10E5 375 300 300 300 150
B620L STAT-1 KO 4.10E5 375 300 300 300 150
B620R STAT-1 KO 4.10E5 375 300 ,<300 300 150
Negative control
(RO)
B623L Wild-type 375 ND ND ND ND
a uPA-SCID mice were injected with 2 105 or 4 105 murine hepatocytes derived from STAT1-deficient (knockout [KO]) mice. Resultant cohorts (RO and IP) were infected
intravenously with 1.3 106 TCID50 mtHCV-Cre.
b ID, identifier.
c HCV RNA levels in serum were measured for up to 8 weeks postinfection. Viral RNA was quantified for up to 8 weeks postinfection using the Roche COBAS AmpliPrep
instrument and the COBAS TaqMan48 HCV test. The limit of detection was 300 IU/ml. ND, not determined.
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were engrafted in immunodeficient liver injury recipients, the re-
sultant simian liver chimeric mice supported persistent HCV in-
fection, albeit with delayed kinetics and lower peak viremia levels
than in control humanizedmice. These data suggest that it may be
possible to establish HCV infection in species more distantly re-
lated to humans. However, since mice and humans diverged phy-
logenetically approximately 65 million years ago, it may be rather
challenging to bridge the genetic gap by viral adaptation despite
HCV’s considerable genetic plasticity.
Over the last few years, other viruses related to HCV in either
the Pegivirus genus, also a part of the Flaviviridae family, or the
Hepacivirus genus have been identified in a variety of species, in-
cluding dogs (46), horses (47, 48), wild mice (49), and rats (50).
An in-depth understanding of how these viruses establish chro-
nicity in species not known to be zoonotic reservoirs forHCVmay
guide further, more directed adaptations of HCV to robustly in-
fect heterologous hosts.
MATERIALS AND METHODS
Cell lines. Huh-7.5 (51), Huh-7.5.1 (52), and HEK293 cells were main-
tained in Dulbecco modified Eagle medium (DMEM) with 10% fetal bo-
vine serum (FBS).
Animals and cell lines.Gt(ROSA)26Sortm1(Luc)Kaelin11 (Rosa26-Fluc),
B6; 129-Gt(ROSA)26Sortm1Joe/J27 (Rosa26-GNZ), B6; 129S2-Scarb1tm1Kri/
J17 (SCARB1/) mice were obtained from The Jackson Laboratory (Bar
Harbor, ME) and Cd81tm1Lvy (CD81/) mice were obtained from the
European Mutant Mouse Archive (Munich, Germany). 129S6/SvEv-
Stat1tm1Rds (STAT1/) and 129S6/SvEvTac (wild-type) mice were ob-
tained from Taconic (Germantown, NY). Human liver-uPA-SCID mice
were generated as previously described (28, 53). Rosa26-Fluc mice con-
tain the firefly luciferase (luc) gene inserted into the Gt.(ROSA)26Sor
locus. Expression of the luciferase gene is blocked by a loxP-flanked STOP
fragment placed between the luc sequence and the Gt.(ROSA)26Sor pro-
moter. Cre recombinase-mediated excision of the transcriptional stop
cassette results in luciferase expression in Cre-expressing tissues. Rosa26-
GNZ knock-in mice have widespread expression of a nucleus-localized
green fluorescent protein/beta-galactosidase fusion protein (GFP-NLS-
GNZ) once an upstream loxP-flanked STOP sequence is removed. When
Cre recombinase is introduced into cells, the resulting GNZ fusion pro-
tein expression allows for enhanced (single-cell level) visualization. All
infections of mice with the indicated strains were performed intrave-
nously.
Mice were bred and maintained at the Laboratory Animal Resources
of Princeton University, Comparative Bioscience Center of the Rocke-
feller University, and at the Animal Resource Center of the University of
Ghent according to guidelines established by the respective Institutional
Animal Care and Use Committees.
Hepatitis C virus. The sequence of the genotype 2a/2a chimera J6/
JFH1 has been deposited in a gene bank (accession number JF343782).
Construction of Jc1 (54), and mCD81/Jc1 (24) (mtHCV) was described
elsewhere. BiCre-Jc1/mCD81 was generated by introducing the L216F,
V388G, andM405T point mutations into BiCre-Jc1 (16) via site-directed
mutagenesis. Jc1(p7nsGluc2a) and Jc1/mCD81(p7nsGluc2a) were gener-
ated by ligating an EcoRI/BsaBI fragment containing core, E1, and parts of
E2 into the EcoRI/BsaBI backbone of Jc1/Flag2(p7nsGluc2a) (29). To
produce infectious virus, Huh-7.5.1 (52) or Huh-7.5 (55) cells were elec-
troporated with in vitro-transcribed full-length HCVRNA (T7 RiboMAX
express large-scale RNA production system; Promega, Madison, WI).
Seventy-two hours postelectroporation, the medium was replaced with
DMEM without FBS, and supernatants were harvested every 6 h starting
from 72 h. Pooled supernatants were filtered through a 0.45-m bottle
top filter (Millipore, Billerica, MA) and concentrated using a stirred cell
(Millipore). Viral titers (TCID50) were determined using Huh-7.5 cells as
previously described (56).
Adenoviruses. Construction of adenoviral constructs encoding
human or mouse CD81, SCARB1, CLDN1, or OCLN was described pre-
viously (16) using the AdEasy adenoviral vector system (Agilent Tech-
nologies, Santa Clara, CA) according to the manufacturer’s instruc-
tions. Briefly, cDNAs encoding HCV entry factors were PCR amplified
and inserted into the pShuttle-CMV (CMV stands for cytomegalovi-
rus) using KpnI/NotI sites. Recombinant pShuttle-CMV plasmids
were linearized with PmeI and ligated to pAdEasy by homologous
recombination followed by electroporation into BJ5183 cells (Agi-
lent). Recombinant pShuttle-pAdEasy constructs were identified by
PacI restriction analysis. All plasmid constructs were verified by DNA
sequencing.
RT-PCR quantification of HCV RNA. Total RNA was isolated from
the indicated mouse tissues using the RNeasy kit (Qiagen, Valencia, CA)
and from serumusing theQIAamp viral RNAminikit. HCV genome copy
number was quantified by one-step reverse transcription-PCR (RT-PCR)
using MultiCode ISOlution (catalog no. 3691; Luminex, Madison, WI),
reverse transcriptase (catalog no. 3693; Luminex, Madison, WI), Tita-
nium Taq (catalog no. S1792; Clontech, Mountain View, CA), and a Step
One Plus quantitative PCR (qPCR) machine (Life Technologies, Carls-
bad, CA), according to manufacturers’ instructions. Data were analyzed
using the MultiCode Analysis Software v1.6.5 (Luminex, Madison, WI).
The following primers were used for the detection of HCV RNA: GCTC
ACGGACCTTTCA (sense) and GGCTCCATCTTAGCCC (antisense).
Quantification of HCV RNA in the chimeric Alb-uPA mice was per-
formed with the Roche COBAS AmpliPrep instrument and the COBAS
TaqMan 48 HCV test.
Antibodies. Blocking antibodies against CD81 (JS81) and IgG1
control antibodies were obtained from BD Biosciences (Franklin
Lakes, NJ). Antibodies against NS5A (56) and E2 (clone AR4A) (33)
and the human IgG1 isotype control (B12) (57) have been described
previously. As a secondary antibody for the detection of anti-NS5A,
Alexa Fluor 647-labeled goat anti-mouse IgG (Life Technologies,
Carlsbad, CA) was used.
Flow cytometry. The frequency of infected hepatocytes and the fre-
quency of infected Huh-7.5 cells after inoculation with sera from infected
mice were confirmed by flow cytometry using an LSRII flow cytometer
(BD Biosciences). For the determination of infection frequency, hepa-
tocytes were isolated from Rosa26-GNZmice, fixed in 4% paraformal-
dehyde, permeabilized in phosphate-buffered saline (PBS) plus 0.01%
Triton X-100, stained with anti-NS5A, and counterstained with
DRAQ5. Data were analyzed using FlowJo software (Treestar Software,
Ashland, OR).
Isolation and infection of murine hepatocytes. C57BL/6 mice were
anesthetized by intraperitoneal injection of a mixture of 100 mg of ket-
amine/kg of body weight and 10 mg/kg xylazine. Livers were perfused
through the portal vein with a chelating solution (0.01MHEPES [pH 7.3]
and 0.5 mM EGTA [pH 8.0] in Ca2/Mg2-free Earle’s balanced salt
solution [EBSS]) at a flow rate of 2 ml/min until the liver bleached, fol-
lowed by 40 ml of collagenase solution (0.01 M HEPES [pH 7.3] and
1 mg/ml collagenase type II in EBSS with Ca2, Mg2, and phenol red).
The digested liver was cut into pieces, transferred into a washing solution
(0.01 M HEPES [pH 7.3] and 10% FBS in DMEM), passed through a
100-m cell strainer, washed, and passed through a 100-m cell strainer.
The resulting cell suspension was passed through a 70-m cell strainer.
The cell suspension was washed three more times with spinning steps at
140 g for 5 min to remove unwanted cellular contaminants. The cells
were resuspended in HBM basal medium after adding HCM Single
Quots (Lonza, Basel, Switzerland), counted, and seeded on collagen-
coated 24-well cell culture plates (Corning, Corning, NY) at a density
of 1.25  105 cells/cm2. The medium was changed every other day.
Confluent monolayers of primary hepatocytes were infected with dif-
ferent doses of Jc1(p7nsGluc2A) or Jc1/mCD81p7nsGluc2A for 12 to
18 h and washed 3 or 4 times with medium, and supernatants were
collected at 48 h following infection. Gaussia luciferase activity was
von Schaewen et al.

















quantified in the cell culture supernatants with a luciferase assay sys-
tem (Promega, Madison, WI) according to the manufacturer’s in-
structions using a Tristar 2 multimode reader LB942 (Berthold Tech-
nologies, Bad Wildbad, Germany).
Bioluminescence im aging. Unless otherwise specified, mice were
injected with 1011 adenoviral particles 24 h prior to intravenous injec-
tion with 2  107 TCID50 HCV-Cre. At 72 h postinfection, mice were
anesthetized using ketamine/xylazine and injected intraperitoneally
with 1.5 mg Luciferin (Caliper Life Sciences, Hopkinton, MA). Biolu-
minescence was measured using an IVIS Lumina II platform (Caliper
Life Sciences).
HCV genome sequencing. Serum samples frommice inoculated with
Jc1/mCD81 were subjected to RNA purification (high pure viral RNA kit;
Roche, Basel, Switzerland) and cDNA amplification (Transcriptor high-
fidelity cDNA synthesis kit; Roche, Basel, Switzerland) with an antisense
primer situated on the NS2 gene. cDNA content was determined by qRT-
PCR. For amplicon library preparation, six contigs which covered the
signal peptide genes of E1, E2, and p7 (amino acids 131 to 813, corre-
sponding to the polyprotein sequence of the reference strain Jc1) were
generated with the Expand Long Range dNTPack kit (Roche, Basel, Swit-
zerland) by nested PCR utilizing 12 primers tagged at the 5= end. Ampli-
cons were prepared individually and quantified by using the Quant-iT
PicoGreen dsDNA (double-stranded DNA) assay kit (Carlsbad, CA).
Emulsion-PCR and bidirectional sequencing reaction was performed us-
ing the 454 platform (Roche, Basel, Switzerland) as described in the GS
FLX emPCR Methods Manual (Roche, Basel, Switzerland). Sequencing
data were analyzed using CLC genomics workbench v4.9 (Aarhus, Den-
mark). Contig assembly and viral population variant calling were per-
formed as described previously (58). The average read depth was 11,000,
ranging from 3,000 to 21,000 reads.
Statistical analysis. Statistical analysis was performed with GraphPad
Prism software (La Jolla, CA). Statistics were calculated using t test or
Kruskal-Wallis one-way analysis of variance (ANOVA). P values less than
0.05 were considered statistically significant.
ACKNOWLEDGMENTS
We thank Jade Xiao, Rachael Labitt, Tamar Frilling, and Sabrina
Woltemate for excellent technical help and Jenna Gaska, Qiang Ding,
and Florian Douam for editing and critical discussions of the manu-
script.
This study is supported by grants from the National Institutes of
Health (R01 AI079031, R01 AI107301, and R21AI117213 to A.P.), a Re-
search Scholar Award from the American Cancer Society (RSG-15-048-
01-MPC to A.P.), a BurroughsWellcome FundAward for Investigators in
Pathogenesis (to A.P.), and a grant from the German Research Founda-
tion (SFB 900/Z1 to S.S.). T.P. was supported by a grant from the Euro-
pean Research Council ERC-2011-StG_281473 (VIRAFRONT) and by a
grant from the Helmholtz Association SO-024. M.V.S. is a recipient of a
postdoctoral fellowship from the German Research Foundation
(Deutsche Forschungsgemeinschaft).
FUNDING INFORMATION
This work, including the efforts of Alexander Ploss, was funded by HHS |
NIH | National Institute of Allergy and Infectious Diseases (NIAID) (R01
AI079031, R01 AI107301, and R21AI117213). This work, including the
efforts of Sebastian Suerbaum, was funded by Deutsche Forschungsge-
meinschaft (DFG) (SFB 900/Z1). This work, including the efforts of
Markus von Schaewen, was funded by Deutsche Forschungsgemeinschaft
(DFG). This work, including the efforts of Thomas Pietschmann, was
funded by EC | European Research Council (ERC) (ERC-2011-StG_
281473-(VIRAFRONT)). This work, including the efforts of Alexander
Ploss, was funded by Burroughs Wellcome Fund (BWF). This work, in-
cluding the efforts of Alexander Ploss, was funded by American Cancer
Society (ACS) (RSG-15-048-01-MPC). This work, including the efforts of
Thomas Pietschmann, was funded by Helmholtz-Gemeinschaft (Helm-
holtz Association) (SO-024).
REFERENCES
1. von Schaewen M, Ploss A. 2014. Murine models of hepatitis C: what can
we look forward to? Antiviral Res 104:15–22. http://dx.doi.org/10.1016/
j.antiviral.2014.01.007.
2. Sandmann L, Ploss A. 2013. Barriers of hepatitis C virus interspecies
transmission. Virology 435:70 – 80. http://dx.doi.org/10.1016/
j.virol.2012.09.044.
3. Ding Q, von Schaewen M, Ploss A. 2014. The impact of hepatitis C virus
entry on viral tropism. Cell Host Microbe 16:562–568. http://dx.doi.org/
10.1016/j.chom.2014.10.009.
4. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. 1999. Hepatitis C
virus and other Flaviviridae viruses enter cells via low density lipoprotein
receptor. Proc Natl Acad Sci U S A 96:12766–12771. http://dx.doi.org/
10.1073/pnas.96.22.12766.
5. Owen DM, Huang H, Ye J, Gale M, Jr. 2009. Apolipoprotein E on
hepatitis C virion facilitates infection through interaction with low-
density lipoprotein receptor. Virology 394:99–108. http://dx.doi.org/
10.1016/j.virol.2009.08.037.
6. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R,
Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding
of hepatitis C virus to CD81. Science 282:938–941. http://dx.doi.org/
10.1126/science.282.5390.938.
7. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G,
Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger
receptor class B type I is a novel candidate receptor for the hepatitis C
virus. EMBO J 21:5017–5025. http://dx.doi.org/10.1093/emboj/cdf529.
8. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B,
Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1
is a hepatitis C virus co-receptor required for a late step in entry. Nature
446:801–805. http://dx.doi.org/10.1038/nature05654.
9. Zheng A, Yuan F, Li Y, Zhu F, Hou P, Li J, Song X, Ding M, Deng H.
2007. Claudin-6 and claudin-9 function as additional coreceptors for
hepatitis C virus. J Virol 81:12465–12471. http://dx.doi.org/10.1128/
JVI.01457-07.
10. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. 2009. Tight
junction proteins claudin-1 and occludin control hepatitis C virus entry
and are downregulated during infection to prevent superinfection. J Virol
83:2011–2014. http://dx.doi.org/10.1128/JVI.01888-08.
11. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice
CM. 2009. Human occludin is a hepatitis C virus entry factor required for
infection of mouse cells. Nature 457:882–886. http://dx.doi.org/10.1038/
nature07684.
12. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis
C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette
D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH,
Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino
L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C
virus entry andpossible targets for antiviral therapy.NatMed 17:589–595.
http://dx.doi.org/10.1038/nm.2341.
13. Sainz B, Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S,
Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Iden-
tification of the Niemann-Pick C1-like 1 cholesterol absorption receptor
as a new hepatitis C virus entry factor. Nat Med 18:281–285. http://
dx.doi.org/10.1038/nm.2581.
14. Martin DN, Uprichard SL. 2013. Identification of transferrin receptor 1
as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A 110:
10777–10782. http://dx.doi.org/10.1073/pnas.1301764110.
15. Wu X, Lee EM, Hammack C, Robotham JM, Basu M, Lang J, Brinton
MA, Tang H. 2014. Cell death-inducing DFFA-like effector b is required
for hepatitis C virus entry into hepatocytes. J Virol 88:8433–8444. http://
dx.doi.org/10.1128/JVI.00081-14.
16. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones
CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss
A. 2011. A genetically humanized mouse model for hepatitis C virus in-
fection. Nature 474:208–211. http://dx.doi.org/10.1038/nature10168.
17. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T,
Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM,
Ploss A. 2013. Completion of the entire hepatitis C virus life cycle in
Infection of Mice with Murine Tropic HCV

















genetically humanized mice. Nature 501:237–241. http://dx.doi.org/
10.1038/nature12427.
18. Michta ML, Hopcraft SE, Narbus CM, Kratovac Z, Israelow B, Souris-
seau M, Evans MJ. 2010. Species-specific regions of occludin required by
hepatitis C virus for cell entry. J Virol 84:11696–11708. http://dx.doi.org/
10.1128/JVI.01555-10.
19. Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R.
2011. Mouse hepatic cells support assembly of infectious hepatitis C virus
particles. Gastroenterology 141:1057–1066. http://dx.doi.org/10.1053/
j.gastro.2011.06.010.
20. Vogt A, Scull MA, Friling T, Horwitz JA, Donovan BM, Dorner M,
Gerold G, Labitt RN, Rice CM, Ploss A. 2013. Recapitulation of the
hepatitis C virus life-cycle in engineered murine cell lines. Virology 444:
1–11. http://dx.doi.org/10.1016/j.virol.2013.05.036.
21. Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, Michalak TI,
Mossman KL, Richardson CD. 2010. Replication of subgenomic hepatitis
C virus replicons in mouse fibroblasts is facilitated by deletion of inter-
feron regulatory factor 3 and expression of liver-specific microRNA 122. J
Virol 84:9170–9180. http://dx.doi.org/10.1128/JVI.00559-10.
22. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. 2006.
Replication of hepatitis C virus (HCV) RNA in mouse embryonic
fibroblasts: protein kinase R (PKR)-dependent and PKR-independent
mechanisms for controlling HCV RNA replication and mediating inter-
feron activities. J Virol 80:7364 –7374. http://dx.doi.org/10.1128/
JVI.00586-06.
23. Nandakumar R, Finsterbusch K, Lipps C, Neumann B, Grashoff M,
Nair S, Hochnadel I, Lienenklaus S, Wappler I, Steinmann E, Hauser H,
Pietschmann T, Kröger A. 2013. Hepatitis C virus replication in mouse
cells is restricted by IFN-dependent and -independent mechanisms. Gas-
troenterology 145:1414–1423.e1. http://dx.doi.org/10.1053/j.gastro.2013
.08.037.
24. Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB,
Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T. 2010.
Adaptation of hepatitis C virus tomouseCD81permits infection ofmouse
cells in the absence of human entry factors. PLoS Pathog 6:e1000978.
http://dx.doi.org/10.1371/journal.ppat.1000978.
25. Frentzen A, Anggakusuma, Gürlevik E, Hueging K, Knocke S, Ginkel C,
Brown RJ, Heim M, Dill MT, Kröger A, Kalinke U, Kaderali L, Kuehnel
F, Pietschmann T. 2014. Cell entry, efficient RNA replication, and pro-
duction of infectious hepatitis C virus progeny in mouse liver-derived
cells. Hepatology 59:78–88. http://dx.doi.org/10.1002/hep.26626.
26. Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE,
Govindarajan S, Shapiro M, St Claire M, Bartenschlager R. 2002. Mu-
tations that permit efficient replication of hepatitis C virus RNA in Huh-7
cells prevent productive replication in chimpanzees. Proc Natl Acad Sci
U S A 99:14416–14421. http://dx.doi.org/10.1073/pnas.212532699.
27. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A,
Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Knete-
man NM. 2001. Hepatitis C virus replication in mice with chimeric hu-
man livers. Nat Med 7:927–933. http://dx.doi.org/10.1038/90968.
28. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K,
Vandekerckhove J, Roskams T, Leroux-Roels G. 2005. Morphological
and biochemical characterization of a human liver in a uPA-SCID mouse
chimera. Hepatology 41:847–856. http://dx.doi.org/10.1002/hep.20657.
29. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED,
Rice CM, Dustin LB. 2008. Cell culture-produced hepatitis C virus does
not infect peripheral bloodmononuclear cells. Hepatology 48:1843–1850.
http://dx.doi.org/10.1002/hep.22550.
30. Safran M, Kim WY, Kung AL, Horner JW, DePinho RA, Kaelin WG, Jr.
2003. Mouse reporter strain for noninvasive bioluminescent imaging of
cells that have undergone Cre-mediated recombination. Mol Imaging
2:297–302. http://dx.doi.org/10.1162/153535003322750637.
31. Awatramani R, Soriano P, Mai JJ, Dymecki S. 2001. An Flp indicator
mouse expressing alkaline phosphatase from the ROSA26 locus. Nat
Genet 29:257–259. http://dx.doi.org/10.1038/ng1101-257.
32. Darzynkiewicz Z, Halicka HD, Zhao H. 2010. Analysis of cellular DNA
content by flow and laser scanning cytometry. Adv Exp Med Biol 676:
137–147. http://dx.doi.org/10.1007/978-1-4419-6199-0_9.
33. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM,
Ploss A, Burton DR, LawM. 2012. Human broadly neutralizing antibod-
ies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl
Acad Sci U S A 109:6205– 6210. http://dx.doi.org/10.1073/pnas
.1114927109.
34. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, Masek
M, Michie SA, Glenn J, Peltz G. 2014. Fialuridine induces acute liver
failure in chimeric TK-NOG mice: a model for detecting hepatic drug
toxicity prior to human testing. PLoSMed 11:e1001628. http://dx.doi.org/
10.1371/journal.pmed.1001628.
35. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. 1995. Complete
reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl
Acad Sci U SA 92:4942–4946. http://dx.doi.org/10.1073/pnas.92.11.4942.
36. Flint M, von Hahn T, Zhang J, Farquhar M, Jones CT, Balfe P, Rice
CM, McKeating JA. 2006. Diverse CD81 proteins support hepatitis C
virus infection. J Virol 80:11331–11342. http://dx.doi.org/10.1128/
JVI.00104-06.
37. Higginbottom A, Quinn ER, Kuo CC, Flint M, Wilson LH, Bianchi E,
Nicosia A, Monk PN, McKeating JA, Levy S. 2000. Identification of
amino acid residues in CD81 critical for interaction with hepatitis C virus
envelope glycoprotein E2. J Virol 74:3642–3649. http://dx.doi.org/
10.1128/JVI.74.8.3642-3649.2000.
38. Chen J, Zhao Y, Zhang C, Chen H, Feng J, Chi X, Pan Y, Du J, Guo M,
Cao H, Chen H, Wang Z, Pei R, Wang Q, Pan L, Niu J, Chen X, Tang
H. 2014. Persistent hepatitis C virus infections and hepatopathological
manifestations in immune-competent humanized mice. Cell Res 24:
1050–1066. http://dx.doi.org/10.1038/cr.2014.116.
39. Anggakusuma, Frentzen A, Gürlevik E, Yuan Q, Steinmann E, Ott M,
Staeheli P, Schmid-Burgk J, Schmidt T, Hornung V, Kuehnel F, Piet-
schmann T. 2015. Control of hepatitis C virus replication in mouse liver-
derived cells by MAVS-dependent production of type I and type III inter-
ferons. J Virol 89:3833–3845. http://dx.doi.org/10.1128/JVI.03129-14.
40. Uprichard SL, Chung J, Chisari FV, Wakita T. 2006. Replication of a
hepatitis C virus replicon clone in mouse cells. Virol J 3:89. http://
dx.doi.org/10.1186/1743-422X-3-89.
41. Zhu Q, Guo JT, Seeger C. 2003. Replication of hepatitis C virus subge-
nomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 77:
9204–9210. http://dx.doi.org/10.1128/JVI.77.17.9204-9210.2003.
42. Abe K, Kurata T, Teramoto Y, Shiga J, Shikata T. 1993. Lack of suscep-
tibility of various primates and woodchucks to hepatitis C virus. J Med
Primatol 22:433–434.
43. Bukh J, Apgar CL, Govindarajan S, Emerson SU, Purcell RH. 2001.
Failure to infect rhesusmonkeyswith hepatitis C virus strains of genotypes
1a, 2a or 3a. J Viral Hepat 8:228–231. http://dx.doi.org/10.1046/j.1365
-2893.2001.00284.x.
44. Sourisseau M, Goldman O, He W, Gori JL, Kiem HP, Gouon-Evans V,
EvansMJ. 2013. Hepatic cells derived from induced pluripotent stem cells
of pigtail macaques support hepatitis C virus infection. Gastroenterology
145:966–969.e7. http://dx.doi.org/10.1053/j.gastro.2013.07.026.
45. Scull MA, Shi C, de Jong YP, Gerold G, Ries M, von Schaewen M,
Donovan BM, Labitt RN, Horwitz JA, Gaska JM, Hrebikova G, Xiao
JW, Flatley B, Fung C, Chiriboga L, Walker CM, Evans DT, Rice CM,
Ploss A. 2015. Hepatitis C virus infects rhesus macaque hepatocytes and
simianized mice. Hepatology 62:57– 67. http://dx.doi.org/10.1002/
hep.27773.
46. Kapoor A, Simmonds P, Gerold G, Qaisar N, Jain K, Henriquez JA,
Firth C, Hirschberg DL, Rice CM, Shields S, Lipkin WI. 2011. Charac-
terization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci
U S A 108:11608–11613. http://dx.doi.org/10.1073/pnas.1101794108.
47. Burbelo PD, Dubovi EJ, Simmonds P, Medina JL, Henriquez JA,
Mishra N, Wagner J, Tokarz R, Cullen JM, Iadarola MJ, Rice CM,
Lipkin WI, Kapoor A. 2012. Serology-enabled discovery of genetically
diverse hepaciviruses in a new host. J Virol 86:6171– 6178. http://
dx.doi.org/10.1128/JVI.00250-12.
48. Kapoor A, Simmonds P, Cullen JM, Scheel TK, Medina JL, Giannitti F,
Nishiuchi E, Brock KV, Burbelo PD, Rice CM, Lipkin WI. 2013. Iden-
tification of a pegivirus (GB virus-like virus) that infects horses. J Virol
87:7185–7190. http://dx.doi.org/10.1128/JVI.00324-13.
49. Kapoor A, Simmonds P, Scheel TK, Hjelle B, Cullen JM, Burbelo PD,
Chauhan LV, Duraisamy R, Sanchez Leon M, Jain K, Vandegrift KJ,
Calisher CH, Rice CM, Lipkin WI. 2013. Identification of rodent ho-
mologs of hepatitis C virus and pegiviruses. mBio 4:e00216-13. http://
dx.doi.org/10.1128/mBio.00216-13.
50. Firth C, Bhat M, Firth MA, Williams SH, Frye MJ, Simmonds P, Conte
JM, Ng J, Garcia J, Bhuva NP, Lee B, Che X, Quan PL, Lipkin WI. 2014.
Detection of zoonotic pathogens and characterization of novel viruses
carried by commensal Rattus norvegicus in New York City. mBio
5:e01933-14. http://dx.doi.org/10.1128/mBio.01933-14.
von Schaewen et al.

















51. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for
subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:
13001–13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
52. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR,
Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis
C virus infection in vitro. ProcNatl Acad Sci U S A 102:9294–9299. http://
dx.doi.org/10.1073/pnas.0503596102.
53. Meuleman P, Vanlandschoot P, Leroux-Roels G. 2003. A simple and
rapid method to determine the zygosity of uPA-transgenic SCID mice.
Biochem Biophys Res Commun 308:375–378. http://dx.doi.org/10.1016/
S0006-291X(03)01388-3.
54. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S,
Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R.
2006. Construction and characterization of infectious intragenotypic and
intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103:
7408–7413. http://dx.doi.org/10.1073/pnas.0504877103.
55. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines
for hepatitis C virus genomic and subgenomic RNA replication. J Virol
76:13001–13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014
.2002.
56. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu
CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM.
2005. Complete replication of hepatitis C virus in cell culture. Science
309:623–626. http://dx.doi.org/10.1126/science.1114016.
57. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW,
Sawyer LS, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E,
Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CF, III. 1994.
Efficient neutralization of primary isolates of HIV-1 by a recombinant
human monoclonal antibody. Science 266:1024–1027. http://dx.doi.org/
10.1126/science.7973652.
58. Irving WL, Rupp D, McClure CP, Than LM, Titman A, Ball JK,
Steinmann E, Bartenschlager R, Pietschmann T, Brown RJ. 2014. De-
velopment of a high-throughput pyrosequencing assay for monitoring
temporal evolution and resistance associated variant emergence in the
hepatitis C virus protease coding-region. Antiviral Res 110:52–59. http://
dx.doi.org/10.1016/j.antiviral.2014.07.009.
Infection of Mice with Murine Tropic HCV









ber 24, 2016 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
